Sat Kartar Life Share Price Today

Sat Kartar Life opens remote e-voting for 14th AGM on Aug 28

Sat Kartar Life Limited has opened remote e-voting for its 14th AGM on August 28, 2026, with voting available from August 25 to 27. Shareholders must hold shares as of August 21 to participate and approve the ₹0.70 per share final dividend and auditor re-appointment.

Sat Kartar Life gets trading approval for 50,400 preferential shares

Sat Kartar Life Limited received NSE approval for the listing of 50,400 equity shares allotted to Non-Promoters via preferential issue. Trading began on July 07, 2026, with a lock-in period effective until January 29, 2027.

Sat Kartar Life secures NABH accreditation valid till May 18, 2029

Sat Kartar Life Limited has received NABH accreditation for its Paschim Vihar facility, valid until May 18, 2029, covering Panchakarma, Shalya Tantra, Naturopathy, and Yoga Treatments. This certification aims to enhance patient confidence and support future empanelments, reinforcing the company's commitment to quality healthcare standards.

Sat Kartar Life files SDD compliance for FY26

Sat Kartar Life Limited submitted its SDD Compliance Certificate for FY26 to the NSE, confirming adherence to SEBI PIT Regulations. The certificate, issued by Rawal & Co, validates the maintenance of a non-tamperable database capturing all 11 required events with no prior non-compliances.

Sat Kartar Life Passes Share Issuance Resolutions

Sat Kartar Life Limited successfully conducted its Extra-Ordinary General Meeting on May 13, 2026, passing two special resolutions regarding the issuance of equity shares and warrants to non-promoters. The meeting, held via video conferencing, saw unanimous approval from shareholders with 1,04,35,956 votes polled in favour. The company has submitted the scrutinizer's report to the National Stock Exchange.

Sat Kartar Life Submits FY26 Earnings Call Transcript With Strategic Growth Roadmap

Sat Kartar Life Limited filed the transcript of its H2 and FY26 Earnings Conference Call with NSE under Regulation 30 of SEBI (LODR) Regulations 2015. Management reported 23% revenue growth crossing ₹200 crore, 73% EBITDA growth, and 74% PAT growth for FY26, while outlining a dual-engine growth strategy combining its core Ayurveda product business with a new hospital vertical targeting 300 beds by FY27 end and 1,000 beds by FY28, supported by a non-exclusive partnership with Jeena Sikho and ongoing expansion into the US market through its Plantomed subsidiary.